Considerations for comparing a test drug with standard of care in phase 2 clinical trials of central nervous system disorders

Drug Information Journal

Volumn 44, Issue 4, 2010, Pages 443-452

  Mallinckrodt, Craig H ^a   Detke, Michael J ^b,c,d,e   Prucka, William R ^a   Ruberg, Stephen J ^a   Molenberghs, Geert ^f,g  

^a ELI LILLY AND COMPANY   (United States)

^b MedAvante Inc   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MCLEAN HOSPITAL   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HASSELT UNIVERSITY   (Belgium)

^g UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Active comparator; Clinical trial; Standard of care

Indexed keywords

DULOXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL RESEARCH; DATA BASE; DRUG EFFECT; DRUG RESEARCH; DRUG SAFETY; HUMAN; PATIENT CARE; PRIORITY JOURNAL;

EID: 77954918727     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286151004400408     Document Type: Article

References (25)

1. International Conference on Harmonization. ICH guidelines, E4: dose-response information to support drug registration; E8, general considerations for clinical trials. http://www.ich.org/cache/compo/276-254-1. html.
2. Keene ON. Phase II trials. In: D'Agostino R, Sullivan L, Massaro J, eds. Wiley Encyclopedia of Clinical Trials. Hoboken, NJ: Wiley; 2007.
3. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med. 2000;133:455-463.
4. Lieberman JA, Greenhouse J, Hamer RM, et al. Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology. 2005;30:445-460.
5. Woods SW, Stolar M, Sernyak MJ, Charney DS. Consistency of atypical antipsychotic superiority to placebo in recent clinical trials. Biol Psychiatry. 2001;49(1):64-70.
6. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-260.
7. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry. 2002;63(3):225-231.
8. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004;24:389-399.
9. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo and paroxetine-controlled trial. Eur Neuropsychopharmacol. 2004;14:457-470.
10. Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry. 2006;21:367-378.
11. Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin. 2007;23:401-416.
12. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002;63(4):308-315.
13. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res. 2002;36:383-390.
14. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007;164:900-909.
15. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull. 2002;36:106-132.
16. Mallinckrodt CH, Prakash A, Houston JP, Swindle R, Detke MJ, Fava M. Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology. 2007;56(2-3):73-85.
17. Mallinckrodt CH, Whitmyer V. Phase III clinical trials. In: D'Agostino R, Sullivan L, Massaro J, eds. Wiley Encyclopedia of Clinical Trials. Hoboken, NJ: Wiley; 2007.
18. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19(1):34-40.
19. Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72(3):115-127.
20. Khan A, Detke M, Khan SR, Mallinckrodt C. Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis. 2003;191(4):211-218.
21. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287:1840-1847.
22. Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, Bandelow B. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry. 2006;67:1741-1746.
23. Berry DA, Stangl DK, eds. Bayesian Biostatistics. New York, NY: Marcel Dekker; 1996.
24. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. New York, NY: Wiley; 2004.
25. Chow S-C, Chang M. Adaptive Design Methods in Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC; 2007.